News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dyslipidemia is a critical risk factor for cardiovascular diseases
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles
_256_384.jpg)
Glenmark released Picture Post Cards on World Vitiligo Day
Subscribe To Our Newsletter & Stay Updated
